NCT05358717: A reported trial by PTC Therapeutics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05358717 |
|---|---|
| Title | A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 3, 2022 |
| Completion date | Feb. 7, 2025 |
| Required reporting date | Feb. 7, 2026, midnight |
| Actual reporting date | Dec. 19, 2025 |
| Date last checked at ClinicalTrials.gov | Feb. 11, 2026 |
| Days late | None |